A Phase I study demonstrates that Avanir Pharmaceuticals' (AVNR) AVP-786 compound has a...


A Phase I study demonstrates that Avanir Pharmaceuticals' (AVNR) AVP-786 compound has a comparable pharmacokinetic, safety and tolerability profile to the company's AVP-923, which is being trialed for use in patients with Alzheimer's disease, Multiple Sclerosis, Parkinson's and autism. As a results, Avanir believes "AVP-786 would be an ideal candidate to test in one or more of our ongoing clinical programs." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs